

Probing the distinct chemosensitivity of *Plasmodium vivax* liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro

Steven Maher (✉ STEVEN.MAHER@UGA.EDU)

University of Georgia

Amélie Vantaux

Institut Pasteur du Cambodge

Victor Chaumeau

Shoklo Malaria Research Unit

Adeline C. Y. Chua

Agency for Science, Technology and Research

Caitlin A. Cooper

University of Georgia

Chiara Andolina

Shoklo Malaria Research Unit

Julie Péneau

Institut Pasteur du Cambodge

Mélanie Rouillier

Medicines for Malaria Venture

Zaira Rizopoulos

Medicines for Malaria Venture

Sivchheng Phal

Institut Pasteur du Cambodge

Eakpor Piv

Institut Pasteur du Cambodge

Chantrea Vong

Institut Pasteur du Cambodge

Sreyvouch Phen

Institut Pasteur du Cambodge

Chansophea Chhin

Institut Pasteur du Cambodge

Baura Tat

Institut Pasteur du Cambodge

Sivkeng Ouk

Institut Pasteur du Cambodge

Bros Doeurk

Institut Pasteur du Cambodge

Saorin Kim

Institut Pasteur du Cambodge

Sangrawee Suriyakan

Shoklo Malaria Research Unit

Praphan Kittiphanakun

Shoklo Malaria Research Unit

Nana Akua Awuku

University of Georgia

Amy J. Conway

University of South Florida

Rays H.Y. Jiang

University of South Florida

Bruce Russell

University of Otago

Pablo Bifani

Agency for Science, Technology and Research

Brice Campo

Medicines for Malaria Venture

François Nosten

Shoklo Malaria Research Unit

Benoît Witkowski

Institut Pasteur du Cambodge

Dennis Kyle

University of Georgia

Research Article

Keywords: Malaria, Prevention of Relapse, Hypnozoite Biology, Extended Assay, Ionophore Controls

DOI: <https://doi.org/10.21203/rs.3.rs-185180/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Improved control of malaria caused by *Plasmodium vivax* can be achieved with the discovery of new antimalarials with radical cure efficacy, including prevention of relapse caused by hypnozoites residing in the liver of vivax patients. We screened several compound libraries against *P. vivax* liver stages, including 1566 compounds against mature hypnozoites, resulting in one drug-like and several probe-like hits useful for investigating hypnozoite biology. Primaquine and tafenoquine, administered in combination with chloroquine, are currently the only FDA-approved antimalarials for radical cure, yet their activity against mature *P. vivax* hypnozoites has not yet been demonstrated in vitro. By developing an extended assay, we show both drugs are individually hypnozonticidal and made more potent when partnered with chloroquine, similar to clinically-relevant combinations. Post-hoc analyses of screening data revealed excellent performance of ionophore controls and the high quality of single point assays, demonstrating a platform able to support the screening of greater compound numbers. A comparison of *P. vivax* liver stage activity data with that of the *P. cynomolgi* blood, *P. falciparum* blood, and *P. berghei* liver stages reveals little activity overlap, indicating that the delivery of new radical curative agents killing *P. vivax* hypnozoites requires an independent, focused drug development test cascade.

Introduction

Malaria is a significant global health problem¹. Human malaria is caused by five different species of the *Plasmodium* parasite, including *Plasmodium vivax*, the most widespread, and *P. falciparum*, the most virulent². As control efforts are reducing falciparum malaria incidence worldwide, controlling vivax malaria is lagging behind³. Upon infection of a new host, *Plasmodium* parasites must complete an asymptomatic and undetectable liver infection prior to initiating a symptomatic and transmittable blood infection. Contributing to the lag in vivax control are hypnozoites remaining in the liver of infected patients; these treatment-insensitive forms resume development days, weeks, or even months after the primary infection, causing a secondary 'relapse' infection and transmission⁴.

There are currently only two FDA-approved drugs for the radical cure of vivax malaria, including relapse prevention, namely, the 8-aminoquinolines (8AQs) primaquine and tafenoquine, which must be co-administered with chloroquine. Chloroquine is a blood schizonticide that has been shown to synergize with 8AQs for radical cure efficacy^{5,6}, but is now compromised by geographical resistance⁷⁻⁹. The potential of 8AQs is further mired by contraindications, such as for glucose-6-phosphate deficient (G6PD) individuals¹⁰. Of note, tafenoquine must be administered with a quantitative test for G6PD and is not currently approved for use with children or pregnant women due to hemolytic potential¹¹. As such, progressing new drugs for treatment of vivax malaria and prevention of relapse are important areas of antimalarial drug discovery and development¹².

Studying *Plasmodium* liver stages requires intricate logistics, expensive materials, and advanced techniques; several recent reports describe critical advancements in this field which have enabled deeper investigation of the liver stages of *P. vivax* and *P. cynomolgi* (a relapsing species closely related to *P. vivax*)¹³⁻¹⁸. Despite these advances, the challenge of studying hypnozoites has left critical questions unanswered. First, for decades, discovery of new antimalarial drugs has been performed with well-established culture models such as the blood stage of *P. falciparum*¹⁹ and the liver stage of rodent malaria species such as *P. berghei*²⁰. Such models have enabled high-throughput screening leading to novel antimalarial development, such as the imidazolopiperazine KAF156^{21,22}. However, these models focus on inhibition of the rapid growth of asexually replicating blood and liver schizonts. As a result, antimalarials currently under development do not address hypnozoite biology, which is defined by long-term quiescence involving mechanisms and phenotypes starkly different than that of a rapidly growing schizont²³. Thus, there are many compounds with known activity against other *Plasmodium* stages and species for which an understanding of hypnozoiticidal activity would greatly help prioritize development. Second, it has been suggested that a pre-screen using one or more of the aforementioned culture models could be utilized as a rapid and inexpensive method to generate a compound library enriched for hypnozoiticidal activity, but this hypothesis has not been tested^{20,24}.

To begin addressing these questions, we screened several small compound collections against *P. vivax* liver stages (PvLS), including the MMV Reference Compound Library, Pathogen Box²⁵, Stasis Box, Malaria Box²⁶, Photodiversity Library, and a collection of 100 compounds with activity against *P. falciparum* stage V gametocytes, with a focus on discovering compounds with activity against mature hypnozoites (Fig. 1A). While our screening platform did identify new hypnozoiticidal compounds, our standard 8-day assay format did not detect 8AQ activity against mature hypnozoites, similar to reports from us and others^{16,17,27}. We therefore developed an assay format with an extended endpoint which not only allows us to observe activity of 8AQs against mature hypnozoites *in vitro*, but also allows us to demonstrate synergy with the partner drug chloroquine; a useful tool for studying the mechanisms of these drugs. To assess the predictive value of alternative screening platforms, we collected activity data from previously-published screens and supplemented this dataset by screening the *P. cynomolgi* asexual blood stage against the Reference Compound Library²⁸. Post-hoc analyses of discovery rates reveals hypnozoites are broadly insensitive to compounds with schizonticidal activity. As other screening platforms do not predict hypnozoiticidal activity, herein we report assay refinements and a screen cascade to increase the predictive value and efficiency of our PvLS platform.

Results

General Overview of Assay Modes, Libraries, and Assay Refinement

Currently defined as a uninucleate form of similar size to the host hepatocyte nucleus, *P. vivax* hypnozoites are known to be sensitive to treatment with several newly developed antimalarials during the first few days after hepatocyte invasion, but are insensitive to these compounds once reaching full maturation between days 4-6 post-infection²⁹⁻³¹. Critically, characterizing the radical cure activity of compounds is dependent on testing mature hypnozoites, and the first *in vitro* assays to demonstrate medium throughput as such were only recently reported^{16,17,32}. These reports describe two distinct *in vitro* assay modes: Prophylactic mode, in which *P. vivax* liver stages are treated before or shortly after hepatocyte infection to assess the sensitivity of early schizonts and immature hypnozoites, and Radical Cure mode, in which liver stages are treated at 5 days post-infection in order to evaluate the sensitivity of late schizonts and mature hypnozoites (Fig. 1B). Prophylactic and Radical Cure single point (SP) runs were performed for the Reference Compound Library (RCL), Pathogen Box (PB), Stasis Box (SB), and Malaria Box (MB), but to manage limited throughput, hit confirmation by dose response (DR) was primarily performed for Radical Cure hits. Likewise, only Radical Cure runs were performed for the Photodiversity Library (PD), a diverse collection of 288 compounds assembled by the University of Sussex and MMV. A summary of SP screen data is shown in Figure 1C. Additionally, several antibiotics (supplementing those in the RCL) were run in Prophylactic and Radical Cure DR assays, while several ionophores and a collection of 100 compounds found active against *P. falciparum* stage V gametocytes^{25,33-36} were assessed in Radical Cure DR assays.

After analyzing the performance of the previously described (v1) DR assay¹⁷, we decided to increase DR assay sensitivity at the cost of throughput by expanding the dose range from 8 points (10 μ M - 46 nM) to 12 points (50 μ M - 280 pM), as well as change from singleton to duplicate wells at each concentration. This refined assay format (v2) resulted in better resolution of PvLS activity and hepatic toxicity, as noted with compound MMV676121 (Fig. S1). This compound was originally detected as a hit in a v1 DR assay and, following several confirmation runs, was thought to be the first new hypnozoitocidal hit discovered from our screen. As follow up, a set of 15 analogs of MMV676121 were assayed to provide an initial structure-activity relationship dataset, but none of the analogs were found selectively active. This lack of activity was explained when we retested MMV676121 in the v2 assay in which it was clarified as nonspecific. We noted loss of hepatic nuclei at all doses that also showed activity against hypnozoites (from 1.85 μ M), thus even though comparing EC₅₀'s for hypnozoitocidal activity (707 nM) and toxicity (2.17 μ M) results in a calculated selectivity index of ~3, these results show concentrations resulting in 15-20% reduction in nuclei are not indicating parasite-specific activity. We therefore began quantifying toxicity in all DR runs by establishing a 20% reduction in hepatic nuclei as a threshold for a calculation of toxicity (CC₂₀), often using operators (i.e. > highest unaffected concentration) as many toxicity curves were either partial or non-sigmoidal. Furthermore, we noted that very often at toxic concentrations the ability of attenuated PvLS parasites to clear from wells was diminished, possibly due to the loss of

hepatocyte-driven clearance mechanisms such as autophagy³⁷. These PvLS parasites were quantified during image analysis and resulted in a bell-shaped dose response curve, which often required masking of the parasite inhibition values of toxicity-affected doses in order to enable a proper curve fit. The ionophore maduramicin is an example; in our refined v2 assay we noted a full sigmoidal dose response curve against mature hypnozoites (EC₅₀ 22 nM) including toxicity and loss of hypnozoite clearance at higher doses (EC₅₀ 4.28 μM), resulting in a selectivity window of >190 (Fig. S1). These methods to remove toxic outliers and resolve selectivity were used to determine the narrow but possibly selective activity of the *P. falciparum* stage V gametocyte inhibitor MMV019204 against mature hypnozoites (Fig. S1).

Because the 8AQs are, in combination with chloroquine, the only FDA-approved drugs for radical cure treatment of *P. vivax*, they are perhaps the most suitable positive control for *in vitro* radical cure drug discovery. However, as shown in our previous report¹⁷, primaquine and tafenoquine were found inactive or weakly active in 8-day Radical Cure assays and therefore could not be used as positive controls. While a screen can be performed without a positive control, in which case activity data is normalized to negative controls or Z factor³⁸, we found the ionophores monensin¹⁷ and nigericin were potent, selective, and able to rapidly clear mature hypnozoites by day 8 post-infection. Therefore, ionophore positive controls were incorporated into our platform as assay development progressed (Fig. 2A, S2). Interestingly, when we exhausted our supply of cryopreserved human hepatocytes and switched lots, we noted diminished activity of monensin against mature hypnozoites, likely due to greater metabolic activity in the new lot as noted from quality-control data from the vendor. We then began using nigericin as the positive control for all DR assays and found it reproducibly and potently active (geometric mean EC₅₀ against hypnozoites in Radical Cure assays: 13 nM, n=9, Fig. 2A).

Screening the Reference Compound Library and 8-Aminoquinoline Assay

The RCL is a collection of 80 newly deployed, developmental, or legacy antimalarials used to validate and characterize MMV-supported small molecule screening platforms. We performed Prophylactic and Radical Cure mode SP assays with the RCL, followed by DR confirmation of hits. As noted in Tables 1 and 2, the four compounds we found most potent against immature hypnozoites and schizonts were phosphatidylinositol 4-kinase (PI4K) inhibitors UCT943 and CC_642944³⁹, eukaryotic elongation factor 2 inhibitor DDD107498⁴⁰, and KAF156²². All four compounds exhibited low nanomolar potency, in agreement with the relative potency range previously described in a Prophylactic assay¹⁷. While an

additional 29 RCL compounds were active against either early or late schizonts, none of the 80 tested, including the 8AQs, were found active against mature hypnozoites in our 8-day Radical Cure assay mode (Tables 1,2).

Synonyms	Class or Target	Schizont Net Growth Area		Hypnozoite Quantity		Nuclei Quantity	
		EC ₅₀ (μM)	Max Inh (%)	EC ₅₀ (μM)	Max Inh (%)	CC ₂₀ (μM)	Max Inh (%)
UCT943	PI4K	0.00175	100	0.00427	100	> 10.0	15.6
CC_642944	PI4K	0.00476	101	101	98.9	> 10.0	1.28
DDD107498 (M5717)	eEF2	0.00257	101	0.0104	100	> 10.0	0.326
KAF156	IZP	0.0141	103	0.0329	105	> 10.0	4.83
Clindamycin	Antibiotic	0.00597	79.5	> 50.0	53.8	> 50.0	5.01
Methotrexate	Folic acid antagonist	0.0428	99.1	> 10.0	12.9	> 10.0	6.07
P218	DHFR	0.0511	101	> 10.0	5.15	> 10.0	9.08
ELQ-300	Cytochrome bc1	0.0576	97.9	> 1.11	71.9	> 10.0	7.2
DSM265	DHODH	0.126	100	> 3.07	37.4	> 3.07	9.06
DSM421	DHODH	0.325	98.8	> 10.0	61.2	> 10.0	4.76
AZ412	V-type H ⁺ -ATPase	0.686	99.7	> 3.33	54.8	> 10.0	2.49
Cycloheximide	Antifungal	1.39	99.6	> 3.33	85.7	> 10.0	8.17
AN13762 (AN762)	Oxaborole, CPSF3	1.63	99.7	> 1.11	93.2	> 10.0	6.64
Chlorproguanil	DHFR	> 1.11	> 1.11	> 10.0	26	> 10.0	9.62
NPC-1161B	8AQ	> 0.370	91.9	> 10.0	41.3	> 10.0	6.73
Pamaquine	8AQ	ND	87.1	> 3.33	27.1	> 10.0	1.25
N-Desethylamodiaquine	4AQ	> 3.33	74.5	> 10.0	15.8	> 10.0	15.3

Trans-Mirincamycin	Antibiotic	ND	72.5	> 10.0	47.4	> 10.0	4.62
Cis-Mirincamycin	Antibiotic	ND	69.3	> 10.0	19.5	> 10.0	13.2
Doxycycline hydrochloride	Antibiotic	> 0.370	68.3	> 10.0	36.7	> 10.0	3.57
Amodiaquine	4AQ	0.0141	65.6	> 10.0	16.3	> 10.0	18.6
Azithromycin	Antibiotic	> 0.370	63.3	> 10.0	24.6	> 10.0	10.7
Artemether	Artemisinin derivative	ND	60.4	> 10.0	35.2	> 10.0	11.4
Tetracycline	Antibiotic	ND	56.7	> 10.0	19.9	> 10.0	3.64
AQ-13	4AQ	ND	56.1	> 10.0	29.4	> 10.0	6.97

Table 1. Confirmed hits from Prophylactic assays of the Reference Compound Library. All EC₅₀'s, CC₂₀'s, and Maximum Inhibition (Max Inh) values are from the highest quality independent experiment. RCL, Reference Compound Library; PI4K, phosphatidyl inositol 4-kinase; eEF2, elongation factor 2; IZP, imidazolopiperazine; DHFR, dihydrofolate reductase; DHODH, dihydroorotate dehydrogenase; CPSF3, cleavage and polyadenylation specificity factor subunit 3; 8AQ, 8-aminoquinoline; 4AQ, 4-aminoquinoline. Included are activity values for selective compounds; activity data for selective and nonselective compounds, as well as structures, can be found in Supplementary Table S1 online.

Synonyms	Library or Collection: Class or Target	Schizont Net Growth Area		Hypnozoite Quantity		Nuclei Quantity	
		EC ₅₀ (μM)	Max Inh (%)	EC ₅₀ (μM)	Max Inh (%)	CC ₂₀ (μM)	Max Inh (%)
Maduramicin	Ionophore: Coccidiostat	0.000705	101	0.0225	120	2.59	89.6
Narasin	Ionophore: Coccidiostat	0.0075	101	0.0646	125	8.8	58.9
Salinomycin	Ionophore: Coccidiostat	0.0402	102	0.112	104	> 10.0	9.18
Lasalocid-A	Ionophore: Coccidiostat	0.0431	100	1.05	78.9	> 10.0	9.93
DDD107498 (M5717)	RCL: Antimalarial, eEF2	0.00235	92.3	> 10.0	21.4	> 10.0	5.09
UCT943	RCL: Antimalarial, PI4K	0.00238	101	> 10.0	54.8	> 10.0	20.5
CC_642944	RCL: Antimalarial, PI4K	0.0239	96.4	> 10.0	6.87	> 10.0	12.1
Cycloheximide	RCL: Antifungal	0.0856	96.3	> 10.0	-3.77	> 10.0	3.7
KAF156	RCL: Antimalarial, IZP	0.33	93.2	> 1.00	52.2	> 1.00	3.09
AZ412	RCL: Antimalarial, V-type H ⁺ -ATPase	0.381	104	> 10.0	29.4	> 10.0	9.37
Thiostrepton	RCL: Antibiotic, rRNA inhibitor	> 3.33	80.2	> 10.0	11.3	> 10.0	4.33
Ro 47-7737	RCL: Antimalarial, 4AQ	> 3.33	70.6	> 10.0	2.26	> 10.0	10.1
DSM265	RCL: Antimalarial, DHODH	> 1.11	69.4	> 10.0	0.114	> 10.0	9.12
SJ733	RCL: Antimalarial, ATP4	ND	56.8	> 50.0	21	> 50.0	8.19
Arterolane, OZ277	RCL: Antimalarial, Artemisinin analog	> 10.0	51.4	> 10.0	40.7	> 10.0	6.82
MMV085499	PB: Malaria, PI4K	0.0012	85.1	> 50.0	24.7	> 50.0	10.3
DDD00108451, MMV667494	PB: Malaria, eEF2	0.00316	103	> 50.0	21.7	> 50.0	14.5

MMV026356	PB: Malaria	0.0266	103	> 50.0	40.9	> 50.0	-0.938
MMV668727	PB: Onchocerciasis	0.19	87.5	> 50.0	50.1	> 50.0	10.2
MMV675993	PB: Cryptosporidiosis	0.294	71.3	> 50.0	14.5	> 50.0	7.81
MMV026020	PB: Malaria	0.418	99.2	> 50.0	31.4	> 50.0	7.48
MMV023860	PB: Malaria	0.57	88.2	> 50.0	-3.82	> 50.0	10.1
MMV024443	PB: Malaria, CDPK1	3.11	84.7	> 50.0	38.5	> 50.0	28.2
MMV688980	PB: Malaria, ATP4	> 16.7	87.6	> 50.0	40.3	> 50.0	1.44
MMV010576	PB: Malaria, Kinase inhibitor	> 16.7	80.2	> 50.0	17.9	> 50.0	23.6
MMV010545	PB: Malaria, CDPK1 or PK7	ND	79.2	> 50.0	40.3	> 50.0	38.1
MMV688548	PB: Toxoplasmosis	> 16.7	76.7	> 50.0	20.4	> 50.0	9.03
MMV023370, MMV676359	PB: Malaria	> 50.0	63.7	> 50.0	36.8	> 50.0	14
MMV690491	SB	0.395	99.2	> 10.0	32.4	> 10.0	3.96
MMV690648	SB	1.23	99	> 10.0	41.5	> 10.0	10.2
MMV396797	MB: Drug like, Heme catabolism	0.599	95.7	> 50.0	-6.1	> 50.0	12.7
MMV019266	MB: Drug like, PKG, Heme catabolism	1.62	92.9	> 50.0	31.3	46.9	48.8
MMV018983	Stage V	4.44	100	1.92	82.8	> 50.0	10.9
MMV021036	Stage V	ND	90.9	19.9	71	> 50.0	7.93
MMV1091186	Stage V	2.86	91	> 50.0	24.8	> 50.0	27.5
MMV019861	Stage V	> 5.56	86.8	> 50.0	38.9	> 16.7	12.7
MMV516035	Stage V	ND	80.2	> 50.0	48.3	> 50.0	7.78

MMV008470	Stage V	> 3.33	72.6	> 10.0	62	> 10.0	3.51
MMV1022644	Stage V	> 3.33	64.7	> 10.0	7.41	> 10.0	0.357
MMV335848	Stage V	ND	60.5	> 10.0	-9.9	> 10.0	13.5
Ciprofloxacin	Antibiotic	> 10.0	59.2	> 10.0	36.3	> 10.0	21.2
Ceftazidime pentahydrate	Antibiotic	> 10.0	47.9	> 10.0	38.3	> 10.0	22

Table 2. Confirmed hits from Radical Cure assays. All EC₅₀'s, CC₂₀'s, and Maximum Inhibition (Max Inh) values are from the highest quality independent experiment. RCL, Reference Compound Library; PB, Pathogen Box; SB, Stasis Box; MB, Malaria Box; Stage V, *P. falciparum* stage V gametocyte active; eEF2, elongation factor 2; PI4K, phosphatidylinositol 4-kinase; IZP, imidazolopiperazine; DHFR, dihydrofolate reductase; DHODH, dihydroorotate dehydrogenase; ATP4, ATPase 4; CDPK1, calcium-dependent protein kinase 1; PK7, protein kinase domain-containing protein 7; PKG, cyclic GMP-dependent protein kinase. Included are activity values for selective compounds; activity data for selective and nonselective compounds, as well as structures, can be found in Supplementary Table S2 online.

As demonstrating 8AQ activity *in vitro* is an important prerequisite for studying the peculiar and elusive mechanisms of these drugs⁴¹, we developed a unique assay mode specifically for 8AQs. Several reports describe the synergistic effect of chloroquine on 8AQ activity against *P. vivax*⁴² *in vivo*, as well as *P. cynomolgi in vivo*⁶, and recently *in vitro*⁴³, thus we hypothesized synergy could be an important element to incorporate into our PvLS platform. Furthermore, we and others have reported 8AQ-treated PvLS take excessive time to clear from culture^{16,27,44}, thus we re-designed the Radical Cure assay to run for 20 days and included chloroquine, primaquine, and tafenoquine alone, in addition to primaquine and tafenoquine in co-treatment with 0.1, 1, or 10 μM chloroquine. Cultures were treated with 1 μM PI4K inhibitor MMV390048 on days 9 and 10 post-infection, 2 days after finishing a 3-day treatment with test compound, to clear schizonts from the culture¹⁶ (Fig. 1B). When tested in this assay mode, primaquine and tafenoquine produced active, yet non-sigmoidal, DR curves against mature hypnozoites, however the curves shifted toward greater potency and were more sigmoidal with the addition of chloroquine (Fig. 2 B,C). In particular, primaquine with 0.1 and 1 μM chloroquine resulted in an EC₅₀ against mature hypnozoites of 16.7 μM and 9.91 μM, respectively, while 0.1 μM chloroquine with tafenoquine, with an EC₅₀ of 198 nM, was found the most potent hypnozoitocidal combination.

Radical Cure Confirmed Activity Summary

To manage available throughput, the majority of SP screening and DR confirmation were performed using the Radical Cure assay mode (Table 2). Building off our previous report on the Radical Cure hypnozoonticidal activity of monensin as well as Prophylactic activity of other ionophores including nigericin, salinomycin, and lasalocid-A¹⁷, we tested these and several other ionophores in Radical Cure assays and found potent hypnozoonticidal activity across this class of compounds. Four ionophores were found much more potent against mature hypnozoites than monensin: maduramicin (EC₅₀ 710 pM), narasin (EC₅₀ 7.5 nM), nigericin (EC₅₀ 13 nM), and salinomycin (EC₅₀ 40 nM). Other than ionophores, of the 1566 compounds tested in Radical Cure assays in this report, the only novel hypnozoonticidal activity found was from 2 of 100 compounds found active against *P. falciparum* stage V gametocytes: MMV018983 (EC₅₀ 1.92-5.16 µM, n=2) and MMV021036 (EC₅₀ 3.63-19.9 µM, n=4).

Run Quality, Cutoff, Predictive Value, and Toxicity

We performed several post-hoc analyses assessing the predictive value of the assay to understand how to better structure the screening cascade to minimize the false discovery rate (FDR). We have previously reported run quality is largely driven by infection rate (PvLS per well), which currently cannot be predicted from run-to-run but can be generally increased by infecting wells with an ample quantity of sporozoites (1-2 x 10⁴) and validated hepatocyte lots¹⁷. We found an infection rate of 40-50 hypnozoites per well was sufficient to generate a Z' factor of 0.0-0.5 (Fig. S2), or enough confidence to simply designate compounds as 'yes/no' with a manageably low FDR which can then be resolved during DR confirmation⁴⁵. To demonstrate how FDR changes in high- versus low-quality assays (as determined by Z' factor), inhibition data from two SP runs of the same library were collected and charted together (Fig. S2). In all multi-run comparisons, the positive control consistently exhibited a narrow deviation around 100% inhibition, while the deviation around the DMSO negative control mean narrowed in the superior run as compared to the inferior run. Thus, despite the variability noted in inactive or untreated wells, we determined our assay consistently detected completely active compounds, such as those with an activity profile like ionophores. However, because we detected a range of partial-actives (with inhibition between 60-75%) and large inactivity window (Figs. S3, S4, S5) we found even a SP run with a robust Z' factor alone could not provide a precise inhibition cutoff for testing putative hits.

To better understand how discovery rates were affected by different cutoffs, the SP and DR data were subjected to Receiver-Operator Characteristic (ROC) analyses⁴⁶. As noted above, toxic compounds often resulted in ambiguous activity at toxic doses. These compounds contribute to the FDR as they can appear active in the SP assay but show non-selectivity when tested in DR (i.e. pyronaridine, Table S1), or they can contribute to the False Omission Rate (FOR) when PvLS are not cleared at toxic doses, (i.e.

MMV019204, Fig. S1). As our screen cascade lacked a method for *a priori* detection of toxicity, the first ROC analysis included all screen data to assess sensitivity and specificity when toxic or nonselective compounds were included (Fig. 3A), while the second ROC analysis only included compounds found nontoxic at 10 μ M in DR assays, to understand the impact of toxic and nonspecific compounds on discovery rates (Fig. 3B). Removal of toxics resulted in better predictive value for most endpoints (for example, AUC increased from 0.7742 to 0.9479 for hypnozoite activity in Prophylactic assays, Fig. 3B), indicating the FDR from SP assays was caused, in part, by toxicity and nonselective activity. To understand if the toxicity data from the SP assay itself could be used to predict toxic or nonselective compounds, a third ROC analysis was performed on SP and DR toxicity data, revealing poor sensitivity when a cutoff of 25% nuclei reduction for putative toxicity was used (Fig. 3C). To measure the magnitude of how including nonselective compounds in DR confirmation affected the FDR and DR confirmation throughput, each toxic compound from the above-mentioned ROC calculations was assessed as either nonselective or selective despite being toxic at 10 μ M (Fig. 3D). When analyzing putative hits for Prophylactic activity against schizonts, for example, we found that 9 compounds exhibited toxicity at 10 μ M in the DR assay, and of those, 3 exhibited a selectivity window and were likely true actives while 6 were either inactive or nonselective.

Cross-comparisons of P. vivax liver stage chemosensitivity to other species and stages

To understand how the chemosensitivity of PvLS compares to other *Plasmodium* species and lifecycle stages, and to investigate if other *Plasmodium* screen platforms are predictive of hypnozoitocidal activity, we first assayed the RCL against *P. cynomolgi* strain Berok K4 asexual blood stages (PcABS) and *P. falciparum* asexual blood stages (PfABS) to produce DR potency data (Fig. 4A). To better understand the effect of serum binding of each compound's potency, the PcABS assay was performed in culture media containing two different serum supplements: one which is physiologically relevant and ideal for PcABS culture (20% *M. fascicularis* serum) and the other used in PfABS assays (0.5% Albumax, a bovine serum-replacement reagent)²⁸. As shown in Figure 4B, we found 6 compounds exhibited a 10-fold shift in PcABS potency due to different serum conditions alone. When the RCL was assayed against both PcABS and PfABS in 0.5% Albumax to determine species specificity, 23 compounds exhibited 5-fold shift in potency between the two species, which suggest differences in drug target or target conformation. When comparing potency against PcABS in 20% *M. fascicularis* serum versus PfABS in 0.5% Albumax, 24 compounds exhibited a 5-fold difference in potency of which 18 compounds exhibited a 10-fold increased potency against PcABS. Potency data from the RCL screen in both PcABS media conditions were then compared to potency data from the RCL screen against PvLS (Fig. 4C). In the PvLS Prophylactic assay, 19 compounds were active against early schizonts, of which 9 compounds demonstrated activity against the early hypnozoites and 14 compounds were active against PcABS. In

the PvLS Radical Cure assay, 9 compounds were active against the late schizonts, of which 1 compound was active against the mature hypnozoites and 8 compounds were active against PcABS.

We next expanded the cross species and lifecycle stage comparisons by gathering SP activity data from three publications and the publicly-available Pathogen box background data and aligning the activity data by compound for side-by-side comparisons to the *P. berghei* sporozoite and liver stage (PbLS), the PcABS, the *P. falciparum* gametocyte stages, and the PfABS^{24,25,28,47}. We first calculated additional ROC curves by simplifying the different PvLS endpoints as “active” if >75% inhibition was achieved against either hypnozoites or schizonts in either mode and looked for predictive value from the other assays (Fig. 5A). Some predictive value was noted with the PcABS assay (AUC=74%), the PfABS assays (AUC=73%), and the PbLS assays (AUC=70%), but none were as predictive as running the compounds through the PvLS SP assay itself (Fig. 3). To understand what sort of activity profile the other assays were predicting, the respective non-vivax assay data were compared to activity against hypnozoites or schizonts in Prophylactic or Radical Cure assays specifically, finding most of the enrichment was for early and late schizonticidal activity, with some enrichment for immature hypnozoite activity (Fig. 5B-D). Lastly, because toxicity was found to contribute to FDR in our SP screen, we performed a ROC plot on HepG2 toxicity data from the PB²⁵, finding almost no predictive value the toxicity noted with primary hepatocytes in our assays (AUC=62%, Fig. 5A).

Discussion

From late 2016 to early 2020, over 20 Single Point (SP) and 58 dose response (DR) plate runs were performed at Shoklo Malaria Research Unit, Thailand, and Institute Pasteur of Cambodia, resulting in data for 1566 test compounds (Fig. 1A), including 1270 compounds tested for Prophylactic activity and 1456 compounds tested for Radical Cure activity in SP assays (Fig. 1B,C).

At the start of screening, every compound and SP library was ran in both Prophylactic and Radical Cure modes, but after finding no new activity against mature hypnozoites in the RCL (Tables 1, 2) and publication that drug screening against *P. berghei* liver stage schizonts is capable of detecting Prophylactic activity against *P. vivax* schizonts²⁰, we determined the assay’s sporozoite-limited throughput should be dedicated primarily to finding Radical Cure hits, especially against mature hypnozoites. Several elements of the assay were refined to provide better activity data and improve workflow (Figs. S1, S7, Methods).

Our Radical Cure-focused SP cascade resulted in no new hits against mature hypnozoites as DR assays alone were used to identify mature hypnozoite activity data for additional ionophores and two

compounds, MMV018983 and MMV021036, first identified as active against *P. falciparum* stage V gametocytes. MMV018983 is a thiourea-hydrazone and not drug-like but could be used as a chemical probe, however MMV021036 is an aminothiazole and could be a suitable starting point for medicinal chemistry optimization⁴⁸. Like MMV018983, the additional ionophore hits could be used as chemical probes for investigating hypnozoite biology. Maduramicin, narasin, and salinomycin can all transport Na⁺ and have been hypothesized to kill *Plasmodium* and the related apicomplexan parasite *Toxoplasma in vitro* by disrupting ion gradients, especially proton gradients needed for proton exchangers, ultimately responsible for transporting Ca²⁺ into the acidocalcisome⁴⁹⁻⁵¹. Similarly, nigericin is a H⁺ and K⁺ antiporter⁵² and also could cause deacidification of the acidocalcisome by directly disrupting intrahepatic or intraparasitic proton gradients. However, we have not attempted to confirm the presence of an acidocalcisome in hypnozoites nor have we confirmed the mechanism of action of ionophores against hypnozoites. As Ca²⁺ signaling has been shown to be essential for other critical lifecycle progressions in *Plasmodium*, if hypnozoites do possess an active acidocalcisome, this organelle could play a critical role in either maintaining or release from dormancy and would be an attractive target for biological and therapeutic research⁵³.

Despite the lack of hypnozoiticidal activity in the libraries we screened, interesting trends in schizonticidal activity were noted (Table 2). While most compounds with activity against late PvLS schizonts exhibited lesser potency than that exhibited when tested against other *Plasmodium* species and stages, three compounds exhibited more potency against late PvLS schizonts, indicating their mechanisms or targets could be distinctly important to the liver stage or *P. vivax* (Fig. S6). We found the PI4K inhibitor analog MMV085499⁵⁴ potent against late PvLS schizonts (EC₅₀ 1.2 nM) but was reported much less potent against *P. berghei* sporozoites (EC₅₀ 280 nM) and the PfABS (EC₅₀ in strains 3D7, Dd2, W2 ranged from 95-212nM)²⁵. This activity profile is unlike other PI4K inhibitors, such as MMV390048, which was relatively equipotent against the PfABS⁵⁵ (EC₅₀ 28 nM) and late PvLS schizonts (EC₅₀ 7 nM, n=40, Fig. 2A). Previously described as interfering with merozoite egress⁵⁶, MMV026356 potently inhibited late PvLS schizonts (EC₅₀ 26.6 nM) and completely eliminated schizont and hypnozoites in Prophylactic assays, but was reported much less potent against *P. berghei* sporozoites (EC₅₀ 1.6 μM), the PfABS (EC₅₀ in strains 3D7, Dd2, W2 ranged from 283-597 nM), and inactive in the PcABS in a SP screen (57.5% inhibition)^{25,28}. MMV023860 was modestly potent against late PvLS schizonts (EC₅₀ 570 nM) but only micromolar potent against *P. berghei* sporozoites (EC₅₀ 1.8 μM) and the PfABS (EC₅₀ in strains 3D7, Dd2, W2 ranged from 1.5-1.9 μM), yet this compound was a top-tier hit against the PcABS (81.4% inhibition)^{25,28} suggesting the unknown target could have a distinct role in the relapsing clade of malaria species. Three compounds from the PB demonstrated complete inhibition of early schizonts and immature hypnozoites in a SP assay as well as submicromolar potency against late schizonts: MMV668727 (EC₅₀ 190 nM), MMV675993 (EC₅₀ 294 nM) and MMV026020 (EC₅₀ 418 nM). MMV668727, a PI4K inhibitor analog, is characterized as an onchocerciasis-active²⁵ while MMV675993

is characterized as a cryptosporidiosis-active²⁵ but has also been reported to have activity against the pathogenic free-living amoeba *Balamuthia mandrillaris* (EC₅₀ 6.35 μM)⁵⁷, demonstrating interesting pan-pathogen activity among this set.

In both our previous report¹⁷ and this study we were unable to demonstrate 8AQ activity in an 8-day Radical Cure assay. The inactivity of primaquine could be due to several factors, including the metabolic state of the host hepatocytes, which activate primaquine via cytochrome 2D6⁵⁸, or because three days of treatment *in vitro* does not reproduce the 7-14 day regimen used clinically for radical cure⁵⁹. While the role of hepatic metabolism on the antirelapse efficacy of tafenoquine is unresolved^{9,60}, three days of treatment *in vitro* should be sufficient as a single dose in coadministration with chloroquine in clinically effective⁹. Alternatively, inactivity in the 8-day assay format is likely due to false omission caused by the slow clearance of treated forms as we were able to show activity of 8AQs alone *in vitro* by modifying the assay to run for 20 days post-infection (Figs. 1B, 2C). Interestingly, after 20 days we noted schizont signal in wells treated with lower, ineffective doses of 8AQ (with or without chloroquine), despite the removal of schizonts at day 9 and 10 post-infection using a PI4K inhibitor¹⁶. This signal can be explained by the presence of schizonts which arose from mature hypnozoites which were refractory to PI4Ki during treatment, this being further evidence of reactivation *in vitro*³¹. The 20-day schizont signal also provides another indication of activity: regardless of the viability of hypnozoites remaining in culture after 20 days, the absence of schizonts at higher doses suggests successful antirelapse activity. Together, these results provide *in vitro* confirmation of experimental and anecdotal evidence of synergy between 8AQs and chloroquine, which has yet to be demonstrated for *P. vivax*, and has only been recently been reported for primaquine-treated *P. cynomolgi*⁴³. As chloroquine resistance is spreading geographically, this unique assay is an invaluable tool for assessing synergistic combinations prior to lengthy and expensive *in vivo* and clinical studies⁸.

Despite a high FDR across endpoints, analyses of screen data reveals the SP assay suitably predicted true activity against early and late schizonts as well as immature hypnozoites (Fig. 3). Additionally, the activity of ionophore controls against mature hypnozoites was consistently detected in SP assays (Fig. S2). We found toxicity was a frequently-confounding factor leading to the FDR. As an example, the MB compound MMV019266 was disappointing in that it was active against late PvLS schizonts (EC₅₀ 1.62 μM) and most other extra-hepatic stages of the *Plasmodium* lifecycle²⁴ and was originally observed to have activity against mature hypnozoites when tested in the SP screen at 10 μM, but in DR confirmation was found to be slightly toxic above 16.7 μM and therefore was not a true positive (Table S2, Fig. 5B,C). While the FDR could be reduced if toxic compounds were pre-screened out of the cascade, we found including toxic hits in DR confirmation would only minimally impact throughput and prevent an increase in FOR due to the possibility of compounds which are toxic at the SP dose but also selective against

PvLS (Fig. 3D). The nonexistent hit rate for activity against mature hypnozoites in SP assays and remarkably low hit rate for mature hypnozoite activity overall, just 2 of 1562 non-ionophores (<0.12%), was surprising in that many of the libraries we tested were either malaria or other disease-focused and were therefore curated to be enriched for presumably desirable attributes such as *Plasmodium* blood stage activity²⁶. As an example, while many hits were noted in Prophylactic assays (Fig. S4, S5), the MB and SB were almost devoid of activity in Radical Cure assays as only one compound with sub-micromolar activity against late schizonts was found in each library: MMV690491 (EC₅₀ 395 nM) and MMV396797 (EC₅₀ 599 nM, Table 2). To investigate this discrepancy, we generated potency data for the RCL against PcABS and found a high level of agreement for schizonticidal compounds but no overlap with activity against mature hypnozoites (Fig. 4). Likewise, an expanded comparison of our SP PvLS activity data to published SP activity data against multiple *Plasmodium* stages and species found low activity overlap (Fig. 5B-D). This result is indicative of the unique insensitivity of hypnozoites and suggests adding one or more of these other assays as a pre-screen in our cascade would likely not enrich for mature hypnozoite hits and could, in fact, be detrimental by contributing to FOR. Future studies include the pursuit of additional mature hypnozoite hits by screening of larger, more diverse chemical libraries, made possible by the advances and information gained in this report.

Methods

Library Preparation

Small volume 384-well plates (Greiner part 784261) were spotted with 5 μ L of each test and control compound, resulting in a 1000x concentration source plate for a 40 nL pin tool (Fig. S1). For SP assays, libraries were provided preplated at 10 mM in DMSO (MMV). Control compounds primaquine and monensin were plated at 10 mM, MMV390048 (PI4Ki) and atovaquone were plated at 3.3 mM, and nigericin was plated at 200 μ M. For DR assays, serial dilutions were made in DMSO (100%) using a Biomek 4000 (Beckman Coulter). Two DR plate maps were used in this study, termed v1 as originally published¹⁷ and v2 (Fig. S1). The assay steps were unchanged regardless of the map version used. Source plates were sealed and shipped on dry ice to Shoklo Malaria Research Unit in Mae Sot, Thailand or Institute Pasteur in Phnom Penh, Cambodia.

Experimental Mosquito Infections and Ethical Consideration

Mosquitoes were reared and infected with a vivax malaria patient isolate bloodmeal to enable harvesting of sporozoites as previously described¹⁷. The Thai human subjects protocols for this study were approved by the Institutional Ethics Committee of the Thai Ministry of Public Health and the Oxford Tropical Medicine Ethical Committee (TMEC 14-016 and OxTREC 40-14). The Cambodian human subjects protocols for this study were approved by the Cambodian National Ethics Committee for Health Research (100NECHR, 111NECHR, and 113NHECR). Protocols conformed to the Helsinki Declaration on

ethical principles for medical research involving human subjects (version 2002) and informed written consent was obtained for all volunteers or legal guardians.

Hepatocyte Culture, Infection, Treatment, and Immunofluorescent Staining

Three different lots of primary human hepatocytes (BioIVT) were validated for PvLS assays and used in this study: PDC were used first, followed by UBV, and then BGW. Assay plates were seeded, infected, treated, and stained as previously described¹⁷ with the one modification: media change was performed by placing the assay plate, inverted, into a custom-fabricated aluminum holder and spinning at 40 RCF for 30 seconds with the slowest possible acceleration. Plates were then moved into a sterile field, excess spent media was removed by blotting with an autoclaved, lint-free cloth (VWR part 100488-446), and 40 μ L Plate media (BioIVT part Z99029, with 10% bovine sera) was added per well.

Twenty-day 8-aminoquinoline Assay

Cultures were seeded with primary hepatocytes, infected with sporozoites, and treated following the Radical Cure mode. At days 9 and 10 post-infection 1 μ M PI4Ki MMV390048 (MMV) was added to the culture media. Because of added PvLS parasite growth variability per well from such a long-term assay, the number of points in the dose response was cut to 6 (50 μ M – 48 nM in a 1:4 dilution series) to increase replicates per concentration (Fig. S1). At 20 days post-infection, cultures were fixed, stained, imaged, and quantified as described below.

High Content Imaging, and Analysis

Initially, cold-chain shipments were used to return completed assay plates to UGA for high content imaging (HCI) with an ImageXpress (IMX) Micro confocal microscope (Molecular Devices). Assay turnaround was dramatically shortened by the installation of a Lionheart FX imager (Biotek) at IPC. This system was found capable of imaging an entire 384-well plate (4 images per well per channel) in less than 4 hours. Data was either analyzed at IPC or compressed and uploaded to cloud storage for further analysis. We found a 4x objective on the Lionheart provided sufficient image resolution to obtain HCI data highly correlating to that obtained with a 10x objective on the IMX while also reducing imaging time and file size (Fig. S7). Using built-in software (MetaXpress for the IMX and Gen5 for the Lionheart), parasites were masked and quantified for growth area per well. Hypnozoites were defined as parasites having a minimum area of 35 μ m² and maximum area of 150-180 μ m², while schizonts were found to have > 500 μ m² area³⁰.

Normalization, Putative Hit Selection, and Curve Fitting

CDD Vault was used for compound management, plate mapping, normalization, data storage, and visibility. For v1 DR assays, PI4Ki was used as the positive control for normalization of schizonts and hypnozoites in Prophylactic assays as well as schizonts in Radical Cure assays. Monensin was not yet known to have an effect on hypnozoites in Radical Cure assays so data were normalized to DMSO control wells and inhibition was calculated as $100\% - \%$ decrease in hypnozoite quantity. For v2 DR assays, we first used monensin and then nigericin as the positive control for hypnozoites and schizonts in both Prophylactic and Radical Cure assays (Fig. 2A). Similarly, the RCL, SB, and PB were all plated and assayed prior to regular use of ionophore controls, thus PI4Ki was used and normalization performed the same as for DR assays describe above. Later, the MB and PD were plated and assayed with monensin control wells (Fig. S2). Because, prior to the availability of HCl at IPC, imaging and quality assessment of individual SP runs was dependent on shipping and could not be performed until long after runs were complete, several libraries were run twice prior to obtaining results in order to improve the likelihood of obtaining a high-quality run from a single round of shipping. Therefore, multiple SP runs of several libraries were available for comparative analysis (Fig. S3). Schizont and hypnozoite inhibition from two runs of the RCL were compared and a cluster of putative hits was found in both the superior and inferior run at $>75\%$ inhibition, thus this became the cutoff for putative hit confirmation in a DR assay (Fig. 3C). As previously described³⁰, we noted treated parasite clearance was diminished at toxic doses of compound, thus points on DR curves in which toxicity and a bell-shape curve for parasite inhibition were noted were removed for curve fitting (Fig. S1). An EC_{50} value for parasite growth (or CC_{20} value for hepatic toxicity) could not be calculated for most curves with shallow slopes, only one point demonstrating $> 50\%$ inhibition, or with no top plateau, thus a curve was characterized as $> ([\text{maximum}] \text{ with } < 50\% \text{ activity})$ when activity was apparent. Some compound activity resulted in a non-sigmoidal, but possibly active, curve which was characterized as “ND” for “ EC_{50} not determined” (Table 1, Table 2, Table S1, Table S2).

Receiver-operate characteristic Analyses

Receiver-operate characteristic (ROC) curves were calculated by comparing SP and DR activity for all compounds for which both types of data existed. The SP data for ROC analysis were collected from the highest-quality run of SP libraries. When a compound was represented in more than one library, the replicate SP data from each library was kept for downstream analysis. However, for control compounds which were also represented as a test well in the library itself, only the data specifically from the test well (not the control wells) was kept for downstream analysis. The activity of every compound in the full DR dataset was then characterized by separately reviewing and describing each DR curve as inactive, active, or ambiguous. A curve was determined inactive when there was little or no activity at $10 \mu\text{M}$ (the SP dose used), regardless of whether or not the compound appeared active at higher doses when tested from $50 \mu\text{M}$ in the DR assay, while a curve was determined “active” when there was a full or partial inhibition ($>$

60%) or sigmoidal fitting. A curve was determined ambiguous when the activity was likely not due to assay noise but also not sigmoidal (indicating likely nonselective activity), when the maximal inhibition at the highest dose was likely true activity but also not resulting in more than 50-60% inhibition, or when the inflection point of an active curve was directly at or near (less than 1 dilution from) 10 μ M. Finally, the characterized all-inclusive DR dataset was merged with the all-inclusive SP dataset described above and analyzed using the ROC calculation tool in Graphpad Prism.

Cross Species and Stage Comparisons

The RCL was tested against PcABS by serially diluting the 5 mM compound stock three-fold with DMSO (100%) to generate a 10-point DR. A 500-fold dilution (100 nL) of compound from the master plate were spotted onto a 384-well assay plate using the Echo 550 liquid dispenser (Labcyte). The plates were then sealed with a removable foil seal using a PlateLoc Thermal Microplate Sealer (Agilent) until use. Mefloquine (5 mM) and DMSO (100%) were used within the master compound plates as the background and baseline controls respectively. The PcABS SYBRI proliferation assay was performed as previously described²⁸.

Activity data for the *P. berghei* liver stage, *P. falciparum* gametocytes, the *P. cynomolgi* blood stage, the *P. falciparum* blood stage, and HepG2 toxicity data were extracted from the respective publications, loaded into CDD Vault by compound, and exported alongside our PvLS data. Because data was available from multiple different assays against a specific species and stage, to manage the number of comparisons ROC analyses were performed by using the maximum inhibition value from any assay for the respective species and stage combination with two exceptions: in one assay the Malaria Box was tested at 50 μ M against the *P. berghei* liver stage and resulted in inhibition and toxicity for most compounds tested, indicating an excessive dose was used, and Female stage V gametocytes appeared refractory to all Malaria Box compounds, thus only Male data were plotted²⁴. Likewise, the maximum inhibition observed, against either hypnozoites or schizonts in either mode, was used as a single value for PvLS data with 75% inhibition serving as the cutoff for “active”.

Figure Generation and Statistics

Venn diagrams of library size and overlap were created using Meta-Chart (<https://www.meta-chart.com/venn>). Graphpad Prism was used to generate publication-quality charts and calculate EC₅₀ values when displaying multiple independent experiments. CDD Vault was used to fit DR curves and calculate EC₅₀ values from single independent experiments (Table 1, Table 2, Table S1, Table S2). At least two independent experiments were used to confirm the relative potency of all active compounds in Tables

1, 2, S1, and S2 except lasalocid A, cycloheximide, MMV690491, and MMV690648 in Table 2 and S2, for which only one DR run was obtained. Due to logistical considerations, the screening cascade and assay refinement occurred concurrently, thus some of the DR curves described herein are from v1 assays. Because data for each compound was collected from running a specific synthetic batch in one of three lots of primary human hepatocytes infected with *P. vivax* parasites from a unique patient isolate in two different countries, averaging multiple runs was determined to represent too many variables and not properly describe the data, so the run with the highest run quality is shown. Error bars and independent experimental replication are described in respective figure legends. Coefficient of variance (CV) was calculated by $100 \times (\text{Standard Deviation} / \text{Average})$. Z' factor was calculated as previously described, using DMSO control wells as negative control and ionophore control wells as positive control⁴⁵.

Data Availability

Most data generated during this study are included in this published article (and its Supplementary Information files). The raw SP and DR datasets generated and analyzed during this study are available from the corresponding author on reasonable request.

References

- 1 World Health Organization, World Malaria Report/
<https://www.who.int/publications/i/item/9789241565721> (2019).
- 2 Phillips, M. A. *et al.* Malaria. *Nat Rev Dis Primers* **3**, 17050, doi:10.1038/nrdp.2017.50 (2017).
- 3 Chu, C. S. *et al.* Declining Burden of Declining Burden of *Plasmodium vivax* in a Population in Northwestern Thailand from 1995 to 2016 before Comprehensive Primaquine Prescription for Radical Cure. *Am J Trop Med Hyg* **102**, 147-150, doi:10.4269/ajtmh.19-0496 (2020).
- 4 Wells, T. N., Burrows, J. N. & Baird, J. K. Targeting the hypnozoite reservoir of *Plasmodium vivax*: the hidden obstacle to malaria elimination. *Trends Parasitol* **26**, 145-151, doi:10.1016/j.pt.2009.12.005 (2010).
- 5 Schmidt, L. H. Comparative efficacies of quinine and chloroquine as companions to primaquine in a curative drug regimen. *Am J Trop Med Hyg* **30**, 20-25, doi:10.4269/ajtmh.1981.30.20 (1981).
- 6 Dow, G. S. *et al.* Radical curative efficacy of tafenoquine combination regimens in *Plasmodium cynomolgi*-infected Rhesus monkeys (*Macaca mulatta*). *Malar J* **10**, 212, doi:10.1186/1475-2875-10-212 (2011).
- 7 Price, R. N. *et al.* Global extent of chloroquine-resistant *Plasmodium vivax*: a systematic review and meta-analysis. *Lancet Infect Dis* **14**, 982-991, doi:10.1016/S1473-3099(14)70855-2 (2014).

- 8 Baird, J. K. Resistance to chloroquine unhinges vivax malaria therapeutics. *Antimicrob Agents Chemother* **55**, 1827-1830, doi:10.1128/AAC.01296-10 (2011).
- 9 Llanos-Cuentas, A. *et al.* Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. *Lancet* **383**, 1049-1058, doi:10.1016/s0140-6736(13)62568-4 (2014).
- 10 Chu, C. S. *et al.* Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. *PLoS Med* **14**, e1002224, doi:10.1371/journal.pmed.1002224 (2017).
- 11 Commons, R. J., McCarthy, J. S. & Price, R. N. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. *Med J Aust* **212**, 152-153.e151, doi:10.5694/mja2.50474 (2020).
- 12 Campo, B., Vandal, O., Wesche, D. L. & Burrows, J. N. Killing the hypnozoite—drug discovery approaches to prevent relapse in Plasmodium vivax. *Pathog Glob Health* **109**, 107-122, doi:10.1179/2047773215y.0000000013 (2015).
- 13 Demebele, L. *et al.* Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. *Nat Med* **20**, 307-312, doi:10.1038/nm.3461 (2014).
- 14 Demebele, L. *et al.* Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. *PLoS One* **6**, e18162, doi:10.1371/journal.pone.0018162 (2011).
- 15 March, S. *et al.* Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. *Nat Protoc* **10**, 2027-2053, doi:10.1038/nprot.2015.128 (2015).
- 16 Gural, N. *et al.* In Vitro Culture, Drug Sensitivity, and Transcriptome of Plasmodium Vivax Hypnozoites. *Cell Host Microbe* **23**, 395-406.e394, doi:10.1016/j.chom.2018.01.002 (2018).
- 17 Roth, A. *et al.* A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. *Nat Commun* **9**, 1837, doi:10.1038/s41467-018-04221-9 (2018).
- 18 Mikolajczak, S. A. *et al.* Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. *Cell Host Microbe* **17**, 526-535, doi:10.1016/j.chom.2015.02.011 (2015).
- 19 Duffy, S. & Avery, V. M. Development and optimization of a novel 384-well anti-malarial imaging assay validated for high-throughput screening. *Am J Trop Med Hyg* **86**, 84-92, doi:10.4269/ajtmh.2012.11-0302 (2012).
- 20 Antonova-Koch, Y. *et al.* Open-source discovery of chemical leads for next-generation chemoprotective antimalarials. *Science* **362**, doi:10.1126/science.aat9446 (2018).

- 21 Meister, S. *et al.* Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. *Science* **334**, 1372-1377, doi:10.1126/science.1211936 (2011).
- 22 Kuhen, K. L. *et al.* KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. *Antimicrob Agents Chemother* **58**, 5060-5067, doi:10.1128/aac.02727-13 (2014).
- 23 Vivax Sporozoite Consortium. Transcriptome and histone epigenome of Plasmodium vivax salivary-gland sporozoites point to tight regulatory control and mechanisms for liver-stage differentiation in relapsing malaria. *Int J Parasitol* **49**, 501-513, doi:10.1016/j.ijpara.2019.02.007 (2019).
- 24 Van Voorhis, W. C. *et al.* Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond. *PLoS Pathog* **12**, e1005763, doi:10.1371/journal.ppat.1005763 (2016).
- 25 Medicines for Malaria Venture. Pathogen Box Supporting Information. <https://www.mmv.org/mmv-open/pathogen-box/pathogen-box-supporting-information> (2020).
- 26 Spangenberg, T. *et al.* The open access malaria box: a drug discovery catalyst for neglected diseases. *PLoS One* **8**, e62906, doi:10.1371/journal.pone.0062906 (2013).
- 27 Maher, S. P. *et al.* An adaptable soft-mold embossing process for fabricating optically-accessible, microfeature-based culture systems and application toward liver stage antimalarial compound testing. *Lab Chip* **20**, 1124-1139, doi:10.1039/c9lc00921c (2020).
- 28 Chua, A. C. Y. *et al.* Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages. *Nat Commun* **10**, 3635, doi:10.1038/s41467-019-11332-4 (2019).
- 29 Zeeman, A. M. *et al.* PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites. *Antimicrob Agents Chemother* **60**, 2858-2863, doi:10.1128/aac.03080-15 (2016).
- 30 Posfai, D. *et al.* Plasmodium vivax Liver and Blood Stages Recruit the Druggable Host Membrane Channel Aquaporin-3. *Cell Chem Biol* **27**, 719-727.e715, doi:10.1016/j.chembiol.2020.03.009 (2020).
- 31 Voorberg-van der Wel, A. M. *et al.* A dual fluorescent Plasmodium cynomolgi reporter line reveals in vitro malaria hypnozoite reactivation. *Commun Biol* **3**, 7, doi:10.1038/s42003-019-0737-3 (2020).
- 32 Voorberg-van der Wel, A. M. *et al.* Dual-Luciferase-Based Fast and Sensitive Detection of Malaria Hypnozoites for the Discovery of Antirelapse Compounds. *Anal Chem* **92**, 6667-6675, doi:10.1021/acs.analchem.0c00547 (2020).
- 33 Duffy, S. & Avery, V. M. Identification of inhibitors of Plasmodium falciparum gametocyte development. *Malar J* **12**, 408, doi:10.1186/1475-2875-12-408 (2013).

- 34 Plouffe, D. M. *et al.* High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission. *Cell Host Microbe* **19**, 114-126, doi:10.1016/j.chom.2015.12.001 (2016).
- 35 Delves, M. J. *et al.* A high throughput screen for next-generation leads targeting malaria parasite transmission. *Nat Commun* **9**, 3805, doi:10.1038/s41467-018-05777-2 (2018).
- 36 Miguel-Blanco, C. *et al.* Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen. *Nat Commun* **8**, 15160, doi:10.1038/ncomms15160 (2017).
- 37 Prado, M. *et al.* Long-term live imaging reveals cytosolic immune responses of host hepatocytes against Plasmodium infection and parasite escape mechanisms. *Autophagy* **11**, 1561-1579, doi:10.1080/15548627.2015.1067361 (2015).
- 38 Bray MA, Carpenter A., Advanced Assay Development Guidelines for Image-Based High Content Screening and Analysis in Assay Guidance Manual (ed. Markossian S, Sittampalam GS, Grossman A, et al.,) 523 (Eli Lilly & Company and the National Center for Advancing Translational Sciences, 2017).
- 39 Brunschwig, C. *et al.* UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. *Antimicrob Agents Chemother* **62**, doi:10.1128/AAC.00012-18 (2018).
- 40 Baragaña, B. *et al.* A novel multiple-stage antimalarial agent that inhibits protein synthesis. *Nature* **522**, 315-320, doi:10.1038/nature14451 (2015).
- 41 Camarda, G. *et al.* Antimalarial activity of primaquine operates via a two-step biochemical relay. *Nat Commun* **10**, 3226, doi:10.1038/s41467-019-11239-0 (2019).
- 42 Alving, A. S. *et al.* Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. *J Lab Clin Med* **46**, 301-306 (1955).
- 43 Dembélé, L. *et al.* Chloroquine Potentiates Primaquine Activity Against Active and Latent Hepatic Plasmodia. *Antimicrob Agents Chemother*, doi:10.1128/AAC.01416-20 (2020).
- 44 Chua, A. C. Y. *et al.* Hepatic spheroids used as an in vitro model to study malaria relapse. *Biomaterials* **216**, 119221, doi:10.1016/j.biomaterials.2019.05.032 (2019).
- 45 Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen* **4**, 67-73, doi:10.1177/108705719900400206 (1999).
- 46 Smithson, D. C., Shelat, A. A., Baldwin, J., Phillips, M. A. & Guy, R. K. Optimization of a non-radioactive high-throughput assay for decarboxylase enzymes. *Assay Drug Dev Technol* **8**, 175-185, doi:10.1089/adt.2009.0249 (2010).

- 47 Delves, M. *et al.* The activities of current antimalarial drugs on the life cycle stages of *Plasmodium*: a comparative study with human and rodent parasites. *PLoS Med* **9**, e1001169, doi:10.1371/journal.pmed.1001169 (2012).
- 48 Paquet, T., Gordon, R., Waterson, D., Witty, M. J. & Chibale, K. Antimalarial aminothiazoles and aminopyridines from phenotypic whole-cell screening of a SoftFocus(®) library. *Future Med Chem* **4**, 2265-2277, doi:10.4155/fmc.12.176 (2012).
- 49 Marchesini, N., Luo, S., Rodrigues, C. O., Moreno, S. N. & Docampo, R. Acidocalcisomes and a vacuolar H⁺-pyrophosphatase in malaria parasites. *Biochem J* **347 Pt 1**, 243-253 (2000).
- 50 Garcia, C. R. *et al.* Acidic calcium pools in intraerythrocytic malaria parasites. *Eur J Cell Biol* **76**, 133-138, doi:10.1016/S0171-9335(98)80026-5 (1998).
- 51 Lavine, M. D. & Arrizabalaga, G. Analysis of monensin sensitivity in *Toxoplasma gondii* reveals autophagy as a mechanism for drug induced death. *PLoS One* **7**, e42107, doi:10.1371/journal.pone.0042107 (2012).
- 52 Adovelande, J. & Schrével, J. Carboxylic ionophores in malaria chemotherapy: the effects of monensin and nigericin on *Plasmodium falciparum* in vitro and *Plasmodium vinckei petteri* in vivo. *Life Sci* **59**, PL309-315, doi:10.1016/s0024-3205(96)00514-0 (1996).
- 53 Brochet, M. & Billker, O. Calcium signalling in malaria parasites. *Mol Microbiol* **100**, 397-408, doi:10.1111/mmi.13324 (2016).
- 54 Duffy, S. *et al.* Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery. *Antimicrob Agents Chemother* **61**, doi:10.1128/AAC.00379-17 (2017).
- 55 Paquet, T. *et al.* Antimalarial efficacy of MMV390048, an inhibitor of *Plasmodium* phosphatidylinositol 4-kinase. *Sci Transl Med* **9**, doi:10.1126/scitranslmed.aad9735 (2017).
- 56 Patra, A. T. *et al.* Whole-Cell Phenotypic Screening of Medicines for Malaria Venture Pathogen Box Identifies Specific Inhibitors of. *Antimicrob Agents Chemother* **64**, doi:10.1128/AAC.01802-19 (2020).
- 57 Rice, C. A., Lares-Jiménez, L. F., Lares-Villa, F. & Kyle, D. E. Screening of the Open-Source Medicines for Malaria Venture Malaria and Pathogen Boxes To Discover Novel Compounds with Activity against *Balamuthia mandrillaris*. *Antimicrob Agents Chemother* **64**, doi:10.1128/AAC.02233-19 (2020).
- 58 Pybus, B. S. *et al.* The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. *Malar J* **12**, 212, doi:10.1186/1475-2875-12-212 (2013).

59 Rajgor, D. D. *et al.* Antirelapse Efficacy of Various Primaquine Regimens for Plasmodium vivax. *Malar Res Treat* **2014**, 347018, doi:10.1155/2014/347018 (2014).

60 Marcsisin, S. R. *et al.* Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. *Malar J* **13**, 2, doi:10.1186/1475-2875-13-2 (2014).

Declarations

Acknowledgements

We thank the malaria patients of northwestern Thailand and northeastern Cambodia for participation in this study. We thank Celgene for providing analogs of MMV676121. We thank Irene Hallyburton and Mark Anderson of the Dundee Drug Discovery Unit at Dundee University for providing PfABS data. We thank Erika Flannery at Novartis Institute for Tropical Diseases and Jeremy Burrows of Medicines for Malaria Venture for critical review of the manuscript. HCl data from drug studies was produced in part by the Biomedical Microscopy Core at the University of Georgia, supported by the Georgia Research Alliance. The Shoklo Malaria Research Unit is part of the Mahidol Oxford Research Unit, supported by the Wellcome Trust of Great Britain. Funding support was provided by the NUHS (WBS R-571-000-040-133 to P.B.), the Bill & Melinda Gates Foundation (OPP1023601 to D.E.K.), and Medicines for Malaria Venture (RD/2017/0042 to B.W. and A.V., RD/16/1082 and RD/15/0022 to S.P.M. and D.E.K.)

Author Contributions

Conceptualization, S.P.M., B.C., F.N., D.E.K.; Methodology, S.P.M., A.V., V.C., A.C.Y.C., C.A., P.B.; Validation, S.P.M., A.V., A.C.Y.C., C.A.C., M.R., Z.R., N.K.A., B.C.; Formal Analysis, S.P.M., C.A.C., A.C.Y.C., M.R., Z.R., N.K.A., A.J.C., R.H.Y.J.; Investigation, S.P.M., A.V., V.C., A.C.Y.C., C.A.C., C.A., J.P., S. Pha., E.P., C.V., S. Phe., C.C., B.T., S.O., B.D., S.K., S.S., P.K.; Resources, S.P.M., A.V., V.C., C.A.C., C.A., J.P., S.S., P.K., N.K.A., B.R., P.B., F.N., B.W.; Data Curation, S.P.M., C.A.C., M.R., Z.R., N.K.A., B.C.; Writing – Original Draft, S.P.M., A.C.Y.C.; Writing – Review & Editing, S.P.M., A.V., V.C., A.C.Y.C., C.A., Z.R., M.R., F.N., P.B., B.C., D.E.K.; Visualization, S.P.M., A.C.Y.C., C.A.C., R.H.Y.J.; Supervision, S.P.M., A.V., V.C., C.A.C., C.A., J.P., Z.R., M.R., S. Pha., R.H.Y.J., B.C., F.N., B.W., D.E.K.; Project Administration, A.V., V.C., C.A.; Funding Acquisition, S.P.M., A.V., M.R., Z.R., B.C., B.W., D.E.K.

Competing Interests

B.C, M.R., and Z.R. are employees of MMV, the other authors declare no potential conflict of interest.